질 항진균제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Vaginal Antifungals Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,901,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,079,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,737,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 이번에 세계의 질 항진균제 시장에 관한 종합 보고서를 발표했습니다. 시장 성장 촉진요인·동향·기회·과제 등의 중요한 시장 역학을 철저하게 평가하고, 시장 구조에 관한 상세 인사이트를 제공하고 있습니다. 이 조사 리포트는 2025-2032년의 세계 질 항진균제 시장의 예측 성장 궤도를 설명하는 독점 데이터와 통계를 게재하고 있습니다.

주요 인사이트

• 질 항진균제 시장 규모(2025년) : 11억 3,360만 달러
• 시장 예측 금액(2032년) : 13억 7,530만 달러
• 세계 시장 성장률(CAGR 2025-2032년) : 2.8%

질 항진균제 시장 : 조사 범위

질 항진균제는 일반적으로 칸디다 종에 의해 유발되는 외음부 질 칸디다증과 같은 진균 감염증을 치료하는 데 사용되는 필수 의약품입니다. 이러한 치료제는 크림, 좌약, 정제, 연고 등 다양한 형태로 제공되며, 처방전 및 일반의약품(OTC) 사용 모두 가능합니다. 시장은 부인과 클리닉, 소매 약국, 온라인 플랫폼, 병원에 서비스를 제공합니다. 여성 건강에 대한 인식의 확대, 질 감염증 증가, 항진균 치료제에 대한 접근성 향상이 시장 개발에 크게 기여하고 있습니다.

시장 성장 촉진요인:

세계 질 항진균제 시장은 여러 가지 중요한 요인에 의해 주도되고 있습니다. 생활습관 관련 감염의 급증, 항생제 사용량 증가, 당뇨병 환자 증가 등이 진균 감염증의 재발률 증가에 기여하고 있습니다. 또한 빠르고 효과적이며 눈에 잘 띄지 않는 치료 옵션에 대한 소비자의 선호로 인해 OTC 항진균제에 대한 수요가 급증하고 있습니다. 서방형 제제 및 병용요법과 같은 제품 혁신으로 편의성과 치료 순응도가 향상되고 있습니다. 특히 도시 및 반도시 지역에서는 생리 및 질 건강에 대한 의식의 향상 캠페인이 제품 인지도와 보급률을 더욱 높이고 있습니다.

시장 성장 억제요인:

질 항진균제 시장은 유망한 성장세가 예상되지만, 저소득 지역의 낮은 인지도, 질 건강에 대해 이야기하는 것에 대한 사회적 낙인, 항진균제 내성에 대한 우려 증가 등 여러 가지 과제를 안고 있습니다. 오진이나 자가 치료는 부적절한 치료로 이어져 전반적인 효과와 소비자 신뢰를 떨어뜨릴 수 있습니다. 규제적 제약, 특히 새로운 제형과 제형의 경우, 시장 진입을 방해하고 승인을 지연시킬 수 있습니다. 일부 지역에서는 문화적 장벽과 교육 부족이 진균 감염증증의 과소 진단과 과소 치료의 원인이 되기도 합니다.

시장 기회:

질 항진균제 시장의 기회는 개인화된 천연 치료 옵션에 대한 수요 증가에 기인합니다. 식물성 제제 및 프로바이오틱스를 함유한 제제 개발이 증가하고 있으며, 기술 혁신의 여지가 있습니다. 원격의료 서비스의 확대는 세심한 진료와 치료 접근성을 확대하는 데 도움이 될 것입니다. 제약회사와 여성 건강 플랫폼과의 제휴를 통해 더 넓은 시장으로 진출할 수 있습니다. 특히 아시아태평양과 라틴아메리카에서 E-Commerce 기반이 확대되면서 OTC 항진균제 제조업체에 새로운 수입원을 제공합니다. 진단 툴와 자가 진단 키트 증가는 항진균제 치료제의 교차 판매 기회를 창출하고 있습니다.

이 보고서에서 다룬 주요 질문

• 세계 질 항진균제 시장의 성장을 가속하는 주요 요인은?
• 각기 다른 소비자층이 가장 선호하는 제형과 제형은 무엇인가?
• 소비자 행동의 변화와 E-Commerce 동향이 질 항진균제 시장에 어떤 영향을 미치고 있는가?
• 시장의 주요 기업은 어디이며, 성장을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 질 항진균제 시장의 새로운 비즈니스 기회와 장기적 전망은?

목차

제1장 개요

제2장 시장 개요

• 시장의 범위/분류
• 시장의 정의/대상 범위/제한
• 포함과 제외

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 주요 혁신/개발 동향

제4장 주요 성공 요인

• 주요 제조업체에 의한 프로모션 전략
• 주요 규제
• 상환 시나리오
• 파이프라인 분석
• 밸류체인 분석
• PESTEL 분석
• Porter의 산업 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인 : 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 약제별
  • 투여 경로별
  • 유통 채널별
  • 국가별
• 2021년 시장 시나리오

제7장 세계의 질 항진균제 시장 수요(금액 또는 규모) 분석, 2019-2024년

• 과거 시장 금액 분석, 2019-2024년
• 현재 및 향후 시장 금액 예측, 2025-2032년
  • 전년대비 성장 동향 분석
  • 절대적 매출 기회 분석

제8장 세계의 질 항진균제 시장 분석 : 약제별(2019-2024년)

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 약제별(2019-2024년)
• 현재·향후 시장 규모 분석·예측 : 약제별(2025-2032년)
  • Fluconazole
  • Nystatin
  • Flucytosine
  • Clotrimazole
  • Ketoconazole
  • Terbinafine
  • 기타
• 의약품별 시장의 매력 분석

제9장 세계의 질 항진균제 시장 분석 : 투여 경로별(2019-2024년)

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 투여 경로별(2019-2024년)
• 현재·향후 시장 규모 분석·예측 : 투여 경로별(2025-2032년)
  • 경구
  • 국소
• 투여 경로별 시장의 매력 분석

제10장 세계의 질 항진균제 시장 분석 : 유통 채널별(2019-2024년)

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 유통 채널별(2019-2024년)
• 현재·향후 시장 규모 분석·예측 : 유통 채널별(2025-2032년)
  • 원내 약국
  • 소매 약국
  • 온라인 약국
• 유통 채널별 시장의 매력 분석

제11장 세계의 질 항진균제 시장 분석 : 지역별(2019-2024년)

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 지역별(2019-2024년)
• 현재·향후 시장 규모 분석·예측 : 지역별(2025-2032년)
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카
• 지역별 시장의 매력 분석

제12장 북미의 질 항진균제 시장 분석, 2019-2024년

제13장 라틴아메리카의 질 항진균제 시장 분석, 2019-2024년

제14장 유럽의 질 항진균제 시장 분석, 2019-2024년

제15장 동아시아의 질 항진균제 시장 분석, 2019-2024년

제16장 남아시아의 질 항진균제 시장 분석, 2019-2024년

제17장 오세아니아의 질 항진균제 시장 분석, 2019-2024년

제18장 중동 및 아프리카(MEA) 질 항진균제 시장 분석, 2019-2024년

제19장 시장 구조 분석

• 기업 계층별 시장 분석
• 시장 집중
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제20장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마킹
• 경쟁 상세
  • Pfizer Inc.
  • Bausch Health Companies Inc
  • ANI Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals Plc
  • Lupin Limited
  • Mycovia Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Unique Pharmaceuticals
  • PEPTONIC medical AB
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories
  • SCYNEXIS, Inc.
  • Basilea Pharmaceutica Ltd.
  • Astellas Pharma Inc.
  • Grupo Ferrer Internacional, SA
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.

제21장 전제조건과 사용되는 두자어

제22장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for vaginal antifungals. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global vaginal antifungals market from 2025 to 2032.

Key Insights:

• Vaginal Antifungals Market Size (2025E): USD 1,133.60 Million
• Projected Market Value (2032F): USD 1,375.30 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 2.8%

Vaginal Antifungals Market - Report Scope:

Vaginal antifungals are essential medications used to treat fungal infections such as vulvovaginal candidiasis, commonly caused by Candida species. These treatments are available in various forms, including creams, suppositories, tablets, and ointments, catering to both prescription-based and over-the-counter (OTC) usage. The market serves gynecology clinics, retail pharmacies, online platforms, and hospitals. Growing awareness about women's intimate health, rising incidences of vaginal infections, and increased accessibility to antifungal treatments contribute significantly to market development.

Market Growth Drivers:

The global vaginal antifungals market is driven by a number of key factors. A surge in lifestyle-related infections, increased antibiotic use, and a rise in diabetic populations have all contributed to higher rates of recurrent fungal infections. Moreover, consumer preference for quick, effective, and discreet treatment options has led to a spike in demand for OTC antifungal products. Product innovation, such as extended-release formulations and combination therapies, enhances convenience and treatment adherence. Campaigns promoting menstrual and vaginal health awareness further boost product visibility and adoption, especially in urban and semi-urban regions.

Market Restraints:

Despite encouraging growth prospects, the vaginal antifungals market encounters challenges including limited awareness in low-income regions, social stigma around discussing vaginal health, and the growing concern of antifungal resistance. Misdiagnosis and self-medication can lead to improper treatment, reducing overall efficacy and consumer trust. Regulatory constraints, especially for newer formulations and combination products, can hinder market entry and delay approvals. In some regions, cultural barriers and lack of education contribute to underdiagnosis and undertreatment of fungal infections.

Market Opportunities:

Opportunities in the vaginal antifungals market stem from increasing demand for personalized and natural treatment options. The rising trend of plant-based and probiotic-infused formulations provides scope for innovation. Expansion of telehealth services allows discreet consultations, expanding treatment access. Partnerships between pharmaceutical companies and women's wellness platforms enable broader market penetration. Growing e-commerce infrastructure, particularly in Asia Pacific and Latin America, is opening up new revenue streams for manufacturers of OTC antifungal solutions. Enhanced diagnostic tools and self-test kits also create cross-selling opportunities for antifungal therapies.

Key Questions Answered in the Report:

• What are the primary drivers accelerating the growth of the vaginal antifungals market worldwide?
• Which dosage forms and formulations are most preferred across different consumer segments?
• How are changing consumer behaviors and e-commerce trends impacting the vaginal antifungals landscape?
• Who are the leading players in the market, and what strategies are being adopted to sustain growth?
• What are the emerging opportunities and long-term outlook for the vaginal antifungals market?

Competitive Intelligence and Business Strategy:

Prominent players in the vaginal antifungals market, including Lupin Limited, Pfizer Inc., and Bausch Health Companies Inc, are focusing on developing user-centric products that combine efficacy with comfort. Companies are increasingly investing in R&D to introduce extended-release suppositories, multi-symptom relief creams, and probiotic-integrated products. Strategic collaborations with gynecological associations and wellness influencers help increase awareness and product credibility. In addition, expanding retail presence and digital marketing strategies are enabling brands to reach younger, digitally-savvy consumers seeking accessible and private treatment options.

Key Companies Profiled:

• Pfizer Inc.
• Bausch Health Companies Inc
• ANI Pharmaceuticals, Inc.
• Hikma Pharmaceuticals Plc
• Lupin Limited
• Mycovia Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Unique Pharmaceuticals
• PEPTONIC medical AB
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories
• SCYNEXIS, Inc.
• Basilea Pharmaceutica Ltd.
• Astellas Pharma Inc.
• Grupo Ferrer Internacional, S.A.
• Pacgen Life Science Corporation
• NovaDigm Therapeutics, Inc.
• Cidara Therapeutics, Inc.
• Amplyx Pharmaceuticals Inc.

Vaginal Antifungals Industry Research Segments

By Drug:

• Fluconazole
• Nystatin
• Flucytosine
• Clotrimazole
• Ketoconazole
• Terbinafine
• Others

By Route of Administration:

• Oral
• Topical

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Key Innovation / Development Trends

4. Key Success Factors

• 4.1. Promotional Strategies, By Key Manufacturers
• 4.2. Key Regulations
• 4.3. Reimbursement Scenario
• 4.4. Pipeline Analysis
• 4.5. Value Chain Analysis
• 4.6. PESTEL Analysis
• 4.7. Porter's Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure Outlook
  • 5.1.3. Global Antifungal Drugs Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Impact of the COVID-19 Pandemic
  • 5.2.2. Increasing Product Launch Activities
  • 5.2.3. Prevalence of Vaginal Fungal Infections in HRT Patients
  • 5.2.4. High Rates of Vulvovaginal Candidiasis
  • 5.2.5. Impact on Quality-of-Life
  • 5.2.6. Increasing Number of People with Predisposing Conditions Such as Diabetes Treated with SGLT2 Inhibitors
  • 5.2.7. Growing Problems of Azole Resistance
  • 5.2.8. Toxicity of Antifungal Drugs
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Drug
  • 6.1.2. By Route of Administration
  • 6.1.3. By Distribution Channel
  • 6.1.4. By Country
• 6.2. 2021 Market Scenario

7. Global Vaginal Antifungals Market Demand (in Value or Size in US$ Mn) Analysis 2019-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2024
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2025-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Vaginal Antifungals Market Analysis 2019-2032, By Drug

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2019-2024
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2025-2032
  • 8.3.1. Fluconazole
  • 8.3.2. Nystatin
  • 8.3.3. Flucytosine
  • 8.3.4. Clotrimazole
  • 8.3.5. Ketoconazole
  • 8.3.6. Terbinafine
  • 8.3.7. Others
• 8.4. Market Attractiveness Analysis By Drug

9. Global Vaginal Antifungals Market Analysis 2019-2032, By Route of Administration

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2024
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2025-2032
  • 9.3.1. Oral
  • 9.3.2. Topical
• 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Vaginal Antifungals Market Analysis 2019-2032, By Distribution Channel

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2024
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2025-2032
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Vaginal Antifungals Market Analysis 2019-2032, By Region

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2024
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025-2032
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. East Asia
  • 11.3.5. South Asia
  • 11.3.6. Oceania
  • 11.3.7. Middle East and Africa
• 11.4. Market Attractiveness Analysis By Region

12. North America Vaginal Antifungals Market Analysis 2019-2032

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 12.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Drug
  • 12.3.3. By Route of Administration
  • 12.3.4. By Distribution Channel
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Drug
  • 12.4.3. By Route of Administration
  • 12.4.4. By Distribution Channel
• 12.5. Market Trends
• 12.6. Key Market Participants - Intensity Mapping
• 12.7. Drivers and Restraints - Impact Analysis
• 12.8. Country Level Analysis & Forecast
  • 12.8.1. U.S. Vaginal Antifungals Market Analysis
    • 12.8.1.1. Introduction
    • 12.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 12.8.1.2.1. By Drug
      • 12.8.1.2.2. By Route of Administration
      • 12.8.1.2.3. By Distribution Channel
  • 12.8.2. Canada Vaginal Antifungals Market Analysis
    • 12.8.2.1. Introduction
    • 12.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 12.8.2.2.1. By Drug
      • 12.8.2.2.2. By Route of Administration
      • 12.8.2.2.3. By Distribution Channel

13. Latin America Vaginal Antifungals Market Analysis 2019-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 13.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 13.3.1. By Country
    • 13.3.1.1. Mexico
    • 13.3.1.2. Brazil
    • 13.3.1.3. Argentina
    • 13.3.1.4. Rest of Latin America
      • 13.3.1.4.1. By Country
      • 13.3.1.4.2. By Drug
      • 13.3.1.4.3. By Route of Administration
      • 13.3.1.4.4. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Drug
  • 13.4.3. By Route of Administration
  • 13.4.4. By Distribution Channel
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. Mexico Vaginal Antifungals Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.1.2.1. By Drug
      • 13.8.1.2.2. By Route of Administration
      • 13.8.1.2.3. By Distribution Channel
  • 13.8.2. Brazil Vaginal Antifungals Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.2.2.1. By Country
      • 13.8.2.2.2. By Drug
      • 13.8.2.2.3. By Route of Administration
      • 13.8.2.2.4. By Distribution Channel
  • 13.8.3. Argentina Vaginal Antifungals Market Analysis
    • 13.8.3.1. Introduction
    • 13.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.3.2.1. By Drug
      • 13.8.3.2.2. By Route of Administration
      • 13.8.3.2.3. By Distribution Channel

14. Europe Vaginal Antifungals Market Analysis 2019-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 14.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 14.3.1. By Country
    • 14.3.1.1. Germany
    • 14.3.1.2. Italy
    • 14.3.1.3. France
    • 14.3.1.4. U.K.
    • 14.3.1.5. Spain
    • 14.3.1.6. BENELUX
    • 14.3.1.7. Russia
    • 14.3.1.8. Rest of Europe
  • 14.3.2. By Drug
  • 14.3.3. By Route of Administration
  • 14.3.4. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug
  • 14.4.3. By Route of Administration
  • 14.4.4. By Distribution Channel
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Germany Vaginal Antifungals Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.1.2.1. By Drug
      • 14.8.1.2.2. By Route of Administration
      • 14.8.1.2.3. By Distribution Channel
  • 14.8.2. Italy Vaginal Antifungals Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.2.2.1. By Drug
      • 14.8.2.2.2. By Route of Administration
      • 14.8.2.2.3. By Distribution Channel
  • 14.8.3. France Vaginal Antifungals Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.3.2.1. By Drug
      • 14.8.3.2.2. By Route of Administration
      • 14.8.3.2.3. By Distribution Channel
  • 14.8.4. U.K. Vaginal Antifungals Market Analysis
    • 14.8.4.1. Introduction
    • 14.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.4.2.1. By Drug
      • 14.8.4.2.2. By Route of Administration
      • 14.8.4.2.3. By Distribution Channel
  • 14.8.5. Spain Vaginal Antifungals Market Analysis
    • 14.8.5.1. Introduction
    • 14.8.5.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.5.2.1. By Drug
      • 14.8.5.2.2. By Route of Administration
      • 14.8.5.2.3. By Distribution Channel
  • 14.8.6. BENELUX Vaginal Antifungals Market Analysis
    • 14.8.6.1. Introduction
    • 14.8.6.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.6.2.1. By Drug
      • 14.8.6.2.2. By Route of Administration
      • 14.8.6.2.3. By Distribution Channel
  • 14.8.7. Russia Vaginal Antifungals Market Analysis
    • 14.8.7.1. Introduction
    • 14.8.7.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.7.2.1. By Drug
      • 14.8.7.2.2. By Route of Administration
      • 14.8.7.2.3. By Distribution Channel

15. East Asia Vaginal Antifungals Market Analysis 2019-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 15.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Drug
  • 15.3.3. By Route of Administration
  • 15.3.4. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug
  • 15.4.3. By Route of Administration
  • 15.4.4. By Distribution Channel
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. China Vaginal Antifungals Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.1.2.1. By Drug
      • 15.8.1.2.2. By Route of Administration
      • 15.8.1.2.3. By Distribution Channel
  • 15.8.2. Japan Vaginal Antifungals Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.2.2.1. By Drug
      • 15.8.2.2.2. By Route of Administration
      • 15.8.2.2.3. By Distribution Channel
  • 15.8.3. South Korea Vaginal Antifungals Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.3.2.1. By Drug
      • 15.8.3.2.2. By Route of Administration
      • 15.8.3.2.3. By Distribution Channel

16. South Asia Vaginal Antifungals Market Analysis 2019-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 16.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Indonesia
    • 16.3.1.3. Malaysia
    • 16.3.1.4. Thailand
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Drug
  • 16.3.3. By Route of Administration
  • 16.3.4. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Drug
  • 16.4.3. By Route of Administration
  • 16.4.4. By Distribution Channel
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. India Vaginal Antifungals Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.1.2.1. By Drug
      • 16.8.1.2.2. By Route of Administration
      • 16.8.1.2.3. By Distribution Channel
  • 16.8.2. Indonesia Vaginal Antifungals Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.2.2.1. By Drug
      • 16.8.2.2.2. By Route of Administration
      • 16.8.2.2.3. By Distribution Channel
  • 16.8.3. Malaysia Vaginal Antifungals Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.3.2.1. By Drug
      • 16.8.3.2.2. By Route of Administration
      • 16.8.3.2.3. By Distribution Channel
  • 16.8.4. Thailand Vaginal Antifungals Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.4.2.1. By Drug
      • 16.8.4.2.2. By Route of Administration
      • 16.8.4.2.3. By Distribution Channel

17. Oceania Vaginal Antifungals Market 2019-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 17.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 17.3.1. By Country
    • 17.3.1.1. Australia
    • 17.3.1.2. New Zealand
  • 17.3.2. By Drug
  • 17.3.3. By Route of Administration
  • 17.3.4. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug
  • 17.4.3. By Route of Administration
  • 17.4.4. By Distribution Channel
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Country Level Analysis & Forecast
  • 17.7.1. Australia Vaginal Antifungals Market Analysis
    • 17.7.1.1. Introduction
    • 17.7.1.2. Market Analysis and Forecast By Market Taxonomy
      • 17.7.1.2.1. By Drug
      • 17.7.1.2.2. By Route of Administration
      • 17.7.1.2.3. By Distribution Channel
  • 17.7.2. New Zealand Vaginal Antifungals Market Analysis
    • 17.7.2.1. Introduction
    • 17.7.2.2. Market Analysis and Forecast By Market Taxonomy
      • 17.7.2.2.1. By Drug
      • 17.7.2.2.2. By Route of Administration
      • 17.7.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Vaginal Antifungals Market Analysis 2019-2032

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 18.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 18.3.1. By Country
    • 18.3.1.1. GCC Countries
    • 18.3.1.2. Turkiye
    • 18.3.1.3. South Africa
    • 18.3.1.4. North Africa
    • 18.3.1.5. Rest of Middle East and Africa
  • 18.3.2. By Drug
  • 18.3.3. By Route of Administration
  • 18.3.4. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Drug
  • 18.4.3. By Route of Administration
  • 18.4.4. By Distribution Channel
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. GCC Countries Vaginal Antifungals Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.1.2.1. By Drug
      • 18.8.1.2.2. By Route of Administration
      • 18.8.1.2.3. By Distribution Channel
  • 18.8.2. Turkiye Vaginal Antifungals Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.2.2.1. By Drug
      • 18.8.2.2.2. By Route of Administration
      • 18.8.2.2.3. By Distribution Channel
  • 18.8.3. South Africa Vaginal Antifungals Market Analysis
    • 18.8.3.1. Introduction
    • 18.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.3.2.1. By Drug
      • 18.8.3.2.2. By Route of Administration
      • 18.8.3.2.3. By Distribution Channel
  • 18.8.4. North Africa Vaginal Antifungals Market Analysis
    • 18.8.4.1. Introduction
    • 18.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.4.2.1. By Drug
      • 18.8.4.2.2. By Route of Administration
      • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

• 19.1. Market Analysis By Tier of Companies
• 19.2. Market Concentration
• 19.3. Market Share Analysis of Top Players
• 19.4. Market Presence Analysis

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Competition Benchmarking
• 20.3. Competition Deep Dive
  • 20.3.1. Pfizer Inc.
    • 20.3.1.1. Overview
    • 20.3.1.2. Product Portfolio
    • 20.3.1.3. Sales Footprint
    • 20.3.1.4. Key Financials
    • 20.3.1.5. SWOT Analysis
    • 20.3.1.6. Strategic Overview
  • 20.3.2. Bausch Health Companies Inc
    • 20.3.2.1. Overview
    • 20.3.2.2. Product Portfolio
    • 20.3.2.3. Sales Footprint
    • 20.3.2.4. Key Financials
    • 20.3.2.5. SWOT Analysis
    • 20.3.2.6. Strategic Overview
  • 20.3.3. ANI Pharmaceuticals, Inc.
    • 20.3.3.1. Overview
    • 20.3.3.2. Product Portfolio
    • 20.3.3.3. Sales Footprint
    • 20.3.3.4. Key Financials
    • 20.3.3.5. SWOT Analysis
    • 20.3.3.6. Strategic Overview
  • 20.3.4. Hikma Pharmaceuticals Plc
    • 20.3.4.1. Overview
    • 20.3.4.2. Product Portfolio
    • 20.3.4.3. Sales Footprint
    • 20.3.4.4. Key Financials
    • 20.3.4.5. SWOT Analysis
    • 20.3.4.6. Strategic Overview
  • 20.3.5. Lupin Limited
    • 20.3.5.1. Overview
    • 20.3.5.2. Product Portfolio
    • 20.3.5.3. Sales Footprint
    • 20.3.5.4. Key Financials
    • 20.3.5.5. SWOT Analysis
    • 20.3.5.6. Strategic Overview
  • 20.3.6. Mycovia Pharmaceuticals, Inc.
    • 20.3.6.1. Overview
    • 20.3.6.2. Product Portfolio
    • 20.3.6.3. Sales Footprint
    • 20.3.6.4. Key Financials
    • 20.3.6.5. SWOT Analysis
    • 20.3.6.6. Strategic Overview
  • 20.3.7. Glenmark Pharmaceuticals Limited
    • 20.3.7.1. Overview
    • 20.3.7.2. Product Portfolio
    • 20.3.7.3. Sales Footprint
    • 20.3.7.4. Key Financials
    • 20.3.7.5. SWOT Analysis
    • 20.3.7.6. Strategic Overview
  • 20.3.8. Unique Pharmaceuticals
    • 20.3.8.1. Overview
    • 20.3.8.2. Product Portfolio
    • 20.3.8.3. Sales Footprint
    • 20.3.8.4. Key Financials
    • 20.3.8.5. SWOT Analysis
    • 20.3.8.6. Strategic Overview
  • 20.3.9. PEPTONIC medical AB
    • 20.3.9.1. Overview
    • 20.3.9.2. Product Portfolio
    • 20.3.9.3. Sales Footprint
    • 20.3.9.4. Key Financials
    • 20.3.9.5. SWOT Analysis
    • 20.3.9.6. Strategic Overview
  • 20.3.10. Aurobindo Pharma Limited
    • 20.3.10.1. Overview
    • 20.3.10.2. Product Portfolio
    • 20.3.10.3. Sales Footprint
    • 20.3.10.4. Key Financials
    • 20.3.10.5. SWOT Analysis
    • 20.3.10.6. Strategic Overview
  • 20.3.11. Dr. Reddy's Laboratories
    • 20.3.11.1. Overview
    • 20.3.11.2. Product Portfolio
    • 20.3.11.3. Sales Footprint
    • 20.3.11.4. Key Financials
    • 20.3.11.5. SWOT Analysis
    • 20.3.11.6. Strategic Overview
  • 20.3.12. SCYNEXIS, Inc.
    • 20.3.12.1. Overview
    • 20.3.12.2. Product Portfolio
    • 20.3.12.3. Sales Footprint
    • 20.3.12.4. Key Financials
    • 20.3.12.5. SWOT Analysis
    • 20.3.12.6. Strategic Overview
  • 20.3.13. Basilea Pharmaceutica Ltd.
    • 20.3.13.1. Overview
    • 20.3.13.2. Product Portfolio
    • 20.3.13.3. Sales Footprint
    • 20.3.13.4. Key Financials
    • 20.3.13.5. SWOT Analysis
    • 20.3.13.6. Strategic Overview
  • 20.3.14. Astellas Pharma Inc.
    • 20.3.14.1. Overview
    • 20.3.14.2. Product Portfolio
    • 20.3.14.3. Sales Footprint
    • 20.3.14.4. Key Financials
    • 20.3.14.5. SWOT Analysis
    • 20.3.14.6. Strategic Overview
  • 20.3.15. Grupo Ferrer Internacional, S.A.
    • 20.3.15.1. Overview
    • 20.3.15.2. Product Portfolio
    • 20.3.15.3. Sales Footprint
    • 20.3.15.4. Key Financials
    • 20.3.15.5. SWOT Analysis
    • 20.3.15.6. Strategic Overview
  • 20.3.16. Pacgen Life Science Corporation
    • 20.3.16.1. Overview
    • 20.3.16.2. Product Portfolio
    • 20.3.16.3. Sales Footprint
    • 20.3.16.4. Key Financials
    • 20.3.16.5. SWOT Analysis
    • 20.3.16.6. Strategic Overview
  • 20.3.17. NovaDigm Therapeutics, Inc.
    • 20.3.17.1. Overview
    • 20.3.17.2. Product Portfolio
    • 20.3.17.3. Sales Footprint
    • 20.3.17.4. Key Financials
    • 20.3.17.5. SWOT Analysis
    • 20.3.17.6. Strategic Overview
  • 20.3.18. Cidara Therapeutics, Inc.
    • 20.3.18.1. Overview
    • 20.3.18.2. Product Portfolio
    • 20.3.18.3. Sales Footprint
    • 20.3.18.4. Key Financials
    • 20.3.18.5. SWOT Analysis
    • 20.3.18.6. Strategic Overview
  • 20.3.19. Amplyx Pharmaceuticals Inc.
    • 20.3.19.1. Overview
    • 20.3.19.2. Product Portfolio
    • 20.3.19.3. Sales Footprint
    • 20.3.19.4. Key Financials
    • 20.3.19.5. SWOT Analysis
    • 20.3.19.6. Strategic Overview

21. Assumptions and Acronyms Used

22. Research Methodology

관련자료